

ErbB2 and EphA3 as a novel prognostic and therapeutic target of Recurrent Non-functioning Pituitary Adenomas: A pilot study

Ashutosh Rai¹, B D Radotra², S K Gupta³, Rajesh Chhabra³, Pinaki Dutta⁴ ¹Department of Translational and Regenerative Medicine, PGIMER, Chandigarh, India. ² Department of Histopathology, PGIMER, Chandigarh, India. ³ Department of Neurosurgery, PGIMER, Chandigarh, India. ⁴Department of Endocrinology, PGIMER, Chandigarh, India.

*Corresponding Author:

Pinaki Dutta, Dept. of Endocrinology, PGIMER, Chandigarh, India,

Abstract

Introduction: Primary squamous cell carcinoma (SCC) of the thyroid gland is a very rare entity. The prognosis is very poor with a short survival time. The aim of this article is to report a case of a SCC of the thyroid gland in a 68-year-old woman, emphasizing how complicated is the operation and the adequate treatment of this disease.

Case Report: A 68-year-old woman presented with rapidly growing neck mass with hoarseness and compressive symptoms. Physical examination revealed a hard fixed tumor with right sided vocal cord palsy. Histopathological result confirmed the diagnosis of SCC of the thyroid. PET/CT scan excluded the possibility of other primary malignancies. A surgical intervention was performed, however the patient died in the middle of the palliative radiation therapy.

Conclusion: SCC of the thyroid gland is a great challenge for the surgeon and also for the multidisciplinary team to come up with the best treatment option which is suitable for the patient due to its unfavorable prognosis.

Key Words: squamous cell carcinoma; thyroid gland

Introduction

Pituitary adenomas are among the most common intracranial tumors with prevalence ranging from 78 to 94 cases per 100000 [1], 68% of which are macroadenoma. These are benign neoplasms which often grow invasively but very rarely progress to true carcinomas [2]. Although classified as benign, they may cause significant morbidity in affected patients due to aberrant hormone secretion, as well as compressive effects on nearby tissues, such as optic chiasm, or the healthy pituitary leading to hypopituitarism. A sizeable proportion of pituitary adenomas (30%) are NFPA. NFPAs are tumors without a clinical evidence of hormone production. Due to their lack of clinically detectable hormonal activity, they tend to present with mass effects. The molecular pathomechanics of NFPA is not well understood. Treatment of these non-functioning tumors is either surgery or radiotherapy but they have high recurrence rate and associated with severe morbidity [3]. The determinants of tumor recurrence after surgical treatment for NFPA are largely unknown. We, therefore, planned to evaluate the molecular predictors and determinants of tumor recurrence after surgery.

Reversible phosphorylation of RTKs regulates a variety of biological processes including communication, cell growth, proliferation, differentiation, and apoptosis. Dysregulation of kinase signaling pathways is commonly associated with various cancers [4,5]. This aberrant regulation may result from hyperactivation of kinases, mutations or defect in the negative feedback. Characterization of phosphorylation status is critical to the elucidation of signal pathways and to the understanding of tumor genesis.

Therefore identifying aberrantly phosphorylated RTKs will provide an important clue to understanding the mechanism of NFPA pathogenesis, they can be used as predictive measures for aggressive behaviour as well as activated kinases may be specifically targeted using small molecule inhibitors.

Methods

Patients: Tumor samples from 20 (with mean age 43±12.6years) male patients of non-functioning pituitary adenoma from the Department of Neurosurgery, PGIMER, Chandigarh, were selected after obtaining an informed written consent and approval by Institute Ethics Committee (NK/1790/PhD/6957). Patients were divided into two groups non-recurrent (n=10) and recurrent (n=10).

Protein Extraction: we extracted protein using 2%SDS, lysis buffer with phosphatase and protease inhibitor cocktail [6] (Roche, Cat.No.11836153001). The concentration of proteins was measured by Bicinchoninic acid assay (Pierce, Waltham, MA Cat #23225). Phosphoproteins were purified using phosphoprotein purification kit (Qiagen, 37101). Isolated phosphoproteins were separated on 10% SDS-PAGE, followed by immunoblotting with anti-phosphotyrosine antibody. The relative phosphorylation levels of 49 RTKs were analyzed (Fig.1) using the Human Phospho-RTK Array kit (ARY001B, R&D Systems, Minneapolis, MN, USA), according to the manufacturer's protocol.





Figure1: Overview of the experimental design and outcome. Flow chart of both RTK array analysis and technical validation.

The levels of phosphorylation were quantified using ImageJ software and normalized to control spots and the background. Data was recorded as mean pixel density of spots and Student's t-test was performed to compare the RTK phosphorylation level



between recurrent and non-recurrent group

Results

The quantitative raw data has been submitted to Figshare (RTK_NFPA:https://figshare.com/articles/RTK_NFPA_xlsx/7528430). ErbB2, PDGFR beta, SCFR, Trk, VEGFR1, VEGFR2, EphA3, and Alk were significantly hyperphosphorylated in recurrent NFPAs. ErbB2 and EphA3 were found to be 1.5 and 1.9 times hyperphosphorylated in recurrent adenomas (Fig 2).

Figure2: Hyperphosphorylation of receptor tyrosine kinases in recurrent NFPAs. RTK array of both replicates 1 and 2 (A) were quantified and ErbB2, PDGFR beta, SCFR, Trk, VEGFR1, VEGFR2, EphA3, and Alk were found to be significantly hyperphosphorylated in recurrent adenomas(B). $p < 0.01$ (*), $p < 0.001$ (**).

These results suggest that ErbB2 and EphA3 targeting drugs will be useful agent for recurrent NFPAs.

Discussion

Our study suggest that hyperphosphorylation of EphA3 and ErbB2 may play crucial role in tumor development and recurrence. ErbB2 are overexpressed and regulate tumor behaviour of corticotroph and lactotroph [7]. Additional validation study of these targets in preclinical models will be required to advance their use for prognostication and therapeutics Utilization of RTK inhibition could be a turning point for management of recurrent NFPAs.

Acknowledgements

This work was funded by the Department of Biotechnology, India (GrantNo. 6242-P109/RGCB/PMD/DBT/KNMJ.2015 Sept 11, 2015).

Competing interests There is no conflict of interest

References

1. Fernandez A, Karavitaki N, Wass JA.(2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury, Clin Endocrinol (Oxf). Mar;72(3):377-82.
2. Melmed S.(2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol. May;7(5):257-66
3. Greenman Y.(2017) Management of endocrine disease: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas. Eur J Endocrinol. Sep; 177(3):R113-R124
4. Gordana Vlahovic , Jeffrey Crawford.(2003) Activation of Tyrosine Kinases in Cancer. Send to Oncologist. 2003;8(6):531-8
5. Zhenfang Du, Christine M. Lovly. (2018) Mechanisms of receptor tyrosine kinase activation in cancer Molecular Cancer 17:58
6. Ashutosh Rai B.D.Radotra K.K.Mukherjee S.K.Gupta Pinaki Dutta.(2018) Data of phosphoproteomic analysis of non- functioning pituitary adenoma. Data in Brief , 781-786
7. Anat Ben-Shlomo, Odelia Cooper.(2017) The role of tyrosine kinase inhibitors in the treatment of pituitary tumors: from bench to bedside. Curr Opin Endocrinol Diabetes Obes. Aug; 24(4): 301–305.